Semaglutide
Aliases: NN9534 · Ozempic · Wegovy · Rybelsus
Semaglutide is a linear peptide targeting GLP-1R, developed by Novo Nordisk for multiple indications. As of Aug 15, 2024, its highest verified stage is Approved.
Identity
- Generic name
- semaglutide
- Brand names
- Ozempic, Wegovy, Rybelsus
- Development codes
- NN9534
- Sponsor / originator
- Novo Nordisk
- Targets
- GLP-1R
- Route / formulation
- Subcutaneous injection and oral tablet
Development timeline
- Approved· Type 2 diabetes· United States
As of Aug 15, 2024 · Confidence: high
Source: FDA approves Wegovy (semaglutide) for chronic weight managementFDA approved as Ozempic for type 2 diabetes.
- Approved· Obesity· United States
As of Aug 15, 2024 · Confidence: high
Source: FDA approves Wegovy (semaglutide) for chronic weight managementFDA approved as Wegovy for chronic weight management.
- Approved· Cardiovascular risk reduction· United States
As of Aug 15, 2024 · Confidence: high
Source: STEP 1: Semaglutide 2.4 mg once weekly in adults with obesitySELECT trial demonstrated MACE reduction; FDA expanded indication.
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| NCT04184622 | Phase 3 | Completed | 1961 | Mar 1, 2021 |
Readouts
View all →Regulatory approvals
| Jurisdiction | Brand | Indication | Date |
|---|---|---|---|
| United States | Wegovy | Obesity | Jun 4, 2021 |
Deals
View all →Next catalysts
View all →Sources
- registryprimary record
STEP 1: Semaglutide 2.4 mg once weekly in adults with obesity
Novo Nordisk A/S · ClinicalTrials.gov · Dec 20, 2019 · NCT04184622
- regulatoryprimary record
FDA approves Wegovy (semaglutide) for chronic weight management
U.S. Food and Drug Administration · FDA News Release · Jun 4, 2021
- peer-reviewedpeer-reviewed
Efficacy and safety of once-weekly semaglutide 2.4 mg in adults with overweight or obesity
Wilding JPH et al. · New England Journal of Medicine · Mar 18, 2021 · DOI: 10.1056/NEJMoa2032183 · PMID: 33567185